Key result
Pleconaril provided sufficient plasma levels but showed drug accumulation, with no significant differences in viral positivity, hospitalization, or symptoms compared to placebo.
Why the study?
Does pleconaril improve clinical outcomes or reduce viral shedding in infants with enterovirus meningitis?
Population
21 evaluable infants ≤12 months old with suspected enterovirus meningitis
Comparison
Pleconaril 5 mg/kg/dose orally three times a day… vs Placebo for 7 days
Design
RCT, 2:1, Double blind, placebo-controlled
Follow-up
14 days
Authors
Loading...
No role for pleconaril in infant enterovirus meningitis; challenges its therapeutic potential and redirects research to alternatives.
RCT (n=21)
Double-blind
2:1
Does pleconaril improve clinical outcomes or reduce viral shedding in infants with enterovirus meningitis?
In infants with enterovirus meningitis, pleconaril provided sufficient plasma levels but showed drug accumulation and no significant clinical or virologic efficacy compared to placebo.
Abzug et al. (2003) conducted an RCT in Enterovirus meningitis (n=21). Pleconaril vs. Placebo was evaluated on Pharmacokinetics, safety, and efficacy (duration of positivity by culture or PCR, hospitalization, or symptoms). Pleconaril provided sufficient plasma levels but showed drug accumulation, with no significant differences in viral positivity, hospitalization, or symptoms compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: